<![CDATA[CYNAERA]]>https://www.cynaera.com/blogRSS for NodeMon, 20 Apr 2026 01:10:29 GMT<![CDATA[Stage Zero™: When the Immune System Is Active Before It Is Named]]>https://www.cynaera.com/post/stage-zero69e54daa8b434ed4ac31f224Sun, 19 Apr 2026 22:12:23 GMT<![CDATA[CYNAERA Remission Standard™]]>https://www.cynaera.com/post/remission-standard69e4ada98b434ed4ac3099e0Sun, 19 Apr 2026 19:20:47 GMT<![CDATA[Inflammatory Bowel Disease Composite Diagnostic Fingerprint (CDF-IBD™)]]>https://www.cynaera.com/post/cdf-ibd69e488de0c8d230c9e91cfafSun, 19 Apr 2026 10:16:59 GMT<![CDATA[Best Practices for POTS Clinical Trials]]>https://www.cynaera.com/post/pots-clinical-trials69e477828b434ed4ac302d33Sun, 19 Apr 2026 07:11:41 GMT<![CDATA[Personalized CRISPR Remission™ for Long COVID: State-Dependent Gene Editing]]>https://www.cynaera.com/post/crispr-remission-long-covid69e3b5f91810622e926d24a1Sun, 19 Apr 2026 03:36:46 GMT<![CDATA[Rheumatoid Arthritis Composite Diagnostic Fingerprint (CDF-RA™)]]>https://www.cynaera.com/post/cdf-ra69e249cb6df221f3f2ccd501Fri, 17 Apr 2026 16:40:40 GMT<![CDATA[Best Practices for Lyme Disease Clinical Trials]]>https://www.cynaera.com/post/lyme-clinical-trials69dfc26bfe6e9d8715cd8d29Wed, 15 Apr 2026 18:04:07 GMT<![CDATA[Target Readiness Index™ (TRI): CRISPR Target Prioritization Autoimmune Disease & IACCs]]>https://www.cynaera.com/post/target-readiness-index69de5f78934ce577916b68cbTue, 14 Apr 2026 16:53:13 GMT<![CDATA[SymCas™: Symptom Cascade Modeling for Flare Prediction in Infection-Associated Chronic Conditions]]>https://www.cynaera.com/post/symcas69dbf91e8614fb4128b18a90Sun, 12 Apr 2026 21:06:18 GMT<![CDATA[Lyme Disease Prevalence Formula (US-CCUC™ Aligned)]]>https://www.cynaera.com/post/us-ccuc-lyme69dbc6a94760d48e5e8ff289Sun, 12 Apr 2026 19:18:09 GMT<![CDATA[Personalized CRISPR Remission™ for ME/CFS: State-Dependent Gene Editing in a Flare Responsive Neuroimmune Disease]]>https://www.cynaera.com/post/crispr-remission-mecfs69d95b2975afb0779a6fd91bSat, 11 Apr 2026 14:46:34 GMT<![CDATA[CRISPR for Lupus (SLE): State-Dependent Remission, Multiomics, and Environmental Modeling in Precision Medicine]]>https://www.cynaera.com/post/crispr-remission-lupus69d7c3dfc55f668b53074bd4Thu, 09 Apr 2026 16:07:53 GMT<![CDATA[CDF-Lyme™: A Composite Diagnostic Fingerprint for Lyme Disease and Post-Treatment Lyme-Associated Illness]]>https://www.cynaera.com/post/cdf-lyme69d716aa89f9e676eca2a7b3Thu, 09 Apr 2026 04:10:05 GMT<![CDATA[Personalized CRISPR Remission™ for Sarcoidosis: A Model for State-Dependent Precision Medicine]]>https://www.cynaera.com/post/crispr-remission-sarcoidosis69d6882a89f9e676eca1592cWed, 08 Apr 2026 20:31:45 GMT<![CDATA[25+ Long COVID Phenotyping List]]>https://www.cynaera.com/post/long-covid-phenotypes69d6611e5f4a19f844e50de0Wed, 08 Apr 2026 15:09:56 GMT<![CDATA[Personalized CRISPR Remission™ in Melanoma: A State-Dependent Innovation Transforming Durable Response]]>https://www.cynaera.com/post/crispr-remission-melanoma69d507dcb75c5d3058252ff4Tue, 07 Apr 2026 16:35:16 GMT<![CDATA[The Diagnostic Multiplier™: A Framework for Adjusting Disease Prevalence Based on Real World Diagnostic Capture]]>https://www.cynaera.com/post/diagnostic-multiplier69d4f07974eeae096e50c5c6Tue, 07 Apr 2026 12:58:33 GMT<![CDATA[CRISPR Remission for Lyme : A Flare-Aware Personalized Gene Editing Innovation]]>https://www.cynaera.com/post/crispr-remission-lyme69d3b64484368b4841055af4Mon, 06 Apr 2026 17:37:48 GMT<![CDATA[CRISPR Remission for Complex Regional Pain Syndrome (CRPS) : A Flare-Aware Gene Editing Framework]]>https://www.cynaera.com/post/crispr-remission-crps69d26d81f7044e6cf7af920eSun, 05 Apr 2026 16:22:08 GMT<![CDATA[State-Dependent Oral CRISPR Delivery: A Systems Framework for Uptake, EBV Targeting, and Gene Editing Efficiency]]>https://www.cynaera.com/post/oral-crispr69d18ef8f7044e6cf7ae46b7Sun, 05 Apr 2026 04:21:12 GMT